BRPI0806257A2 - método de tratamento, e, uso de uma composição imunoterapêutica - Google Patents

método de tratamento, e, uso de uma composição imunoterapêutica Download PDF

Info

Publication number
BRPI0806257A2
BRPI0806257A2 BRPI0806257-9A BRPI0806257A BRPI0806257A2 BR PI0806257 A2 BRPI0806257 A2 BR PI0806257A2 BR PI0806257 A BRPI0806257 A BR PI0806257A BR PI0806257 A2 BRPI0806257 A2 BR PI0806257A2
Authority
BR
Brazil
Prior art keywords
treatment
immunotherapeutic composition
immune
radiotherapy
chemotherapy
Prior art date
Application number
BRPI0806257-9A
Other languages
English (en)
Inventor
Vincent Brichard
Catherine Marie Ghislaine Gerard
Frederic Francois Eugene Lehmann
Jamila Louahed
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of BRPI0806257A2 publication Critical patent/BRPI0806257A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

MéTODO DE TRATAMENTO, E, USO DE UMA COMPOSIçãO IMUNOTERAPêUTICA. Uma terapia combinada, compreendendo uma imunoterapia com base em um antígeno de tumor ou um seu derivado imunológico e pelo menos um outro tratamento para câncer, tal como quimioterapia, radioterapia e/ou cirurgia.
BRPI0806257-9A 2007-01-08 2008-01-08 método de tratamento, e, uso de uma composição imunoterapêutica BRPI0806257A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0700284.3A GB0700284D0 (en) 2007-01-08 2007-01-08 Combination therapy
PCT/EP2008/050133 WO2008084040A1 (en) 2007-01-08 2008-01-08 Use of mage a3-protein d fusion antigen in immunotherapy combined with surgery, chemotherapy or radiotherapy for the treatment of cancer

Publications (1)

Publication Number Publication Date
BRPI0806257A2 true BRPI0806257A2 (pt) 2011-08-30

Family

ID=37801846

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0806257-9A BRPI0806257A2 (pt) 2007-01-08 2008-01-08 método de tratamento, e, uso de uma composição imunoterapêutica

Country Status (12)

Country Link
US (1) US20100008980A1 (pt)
EP (1) EP2099470A1 (pt)
JP (1) JP2010515670A (pt)
KR (1) KR20090099011A (pt)
CN (1) CN101578105A (pt)
AU (1) AU2008204526A1 (pt)
BR (1) BRPI0806257A2 (pt)
CA (1) CA2674315A1 (pt)
EA (1) EA200900735A1 (pt)
GB (1) GB0700284D0 (pt)
MX (1) MX2009007295A (pt)
WO (1) WO2008084040A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20120400A1 (es) * 2009-05-27 2012-05-04 Glaxosmithkline Biolog Sa Contrucciones de casb7439
US20130031794A1 (en) 2011-08-05 2013-02-07 Duff Jr Ronald Richard RAZOR BLADES WITH ALUMINUM MAGNESIUM BORIDE (AlMgB14)-BASED COATINGS
RU2014122867A (ru) * 2011-12-22 2016-02-20 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Способ лечения рака иммунотерапевтическим средством, специфичным в отношении MAGEA3, совместно с ингибитором BRAF и/или ингибитором MEK
CN111655714A (zh) * 2017-11-08 2020-09-11 阿德瓦希斯公司 来自癌症相关蛋白的免疫原性异变肽及其使用方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235525B1 (en) * 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
CZ298347B6 (cs) * 1998-02-05 2007-09-05 Glaxosmithkline Biologicals S.A. Fúzní protein z rodiny MAGE, kódová sekvence nukleové kyseliny, vektor, hostitelská bunka, vakcina a použití fúzního proteinu pro výrobu vakciny
ATE446106T1 (de) * 2001-11-29 2009-11-15 Dandrit Biotech As Pharmazeutische zusammensetzung zur auslösung einer immunantwort bei einem menschen oder einem tier
CA2653402A1 (en) * 2006-05-26 2007-12-06 Glaxosmithkline Biologicals S.A. Method

Also Published As

Publication number Publication date
WO2008084040A8 (en) 2008-08-28
EP2099470A1 (en) 2009-09-16
CN101578105A (zh) 2009-11-11
US20100008980A1 (en) 2010-01-14
EA200900735A1 (ru) 2010-02-26
KR20090099011A (ko) 2009-09-18
GB0700284D0 (en) 2007-02-14
JP2010515670A (ja) 2010-05-13
WO2008084040A1 (en) 2008-07-17
MX2009007295A (es) 2009-07-14
AU2008204526A1 (en) 2008-07-17
CA2674315A1 (en) 2008-07-17

Similar Documents

Publication Publication Date Title
BR112019021822A2 (pt) Terapia de combinação
PH12016501728A1 (en) Anti-angiogenesis therapy for the treatment of ovarian cancer
MX2017003246A (es) Macropinocitosis de anticuerpos anti-cd46 humanos y agentes terapeuticos dirigidos contra el cancer.
EA201890146A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ
AU2018278311A1 (en) IRE1 small molecule inhibitors
BR112015030377A2 (pt) preparação compreendendo pelo menos um quimioterápico ou substância citotóxica para uso no tratamento de uma doença de um paciente mamífero, preparação e método para tratamento de câncer em um paciente mamífero através de terapia de radiação
EA201991622A1 (ru) Комплексная терапия для лечения рака
CO6612264A2 (es) Proteinas terapeuticas de la union a dll 4
EA201000016A1 (ru) Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями
BR112015019064A2 (pt) métodos de tratamento de melanoma
MX2019010382A (es) Metodo de tratamiento de tumor inmunoterapeutico utilizando un agonista alfa,beta-selectivo del receptor de interleuquina-2 en combinacion con terapia de transferencia celular adoptiva.
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
EA202191257A1 (ru) Противораковая терапия на основе иммуноцитов, связывающих liv1
EP3895725A3 (en) A method for treating tumor by using recombinant interferon with changed spatial configuration
MX2019006331A (es) Métodos para tratar el cáncer usando anticuerpos anti-pd-l1 y antiandrógenos.
BR112018011177A2 (pt) conjugados de citarabina para terapia de câncer
MX2013006758A (es) Peptidos de union a hla derivados de moleculas antigenicas asociadas a la prostata y metodos de uso de los mismos.
CO2022002573A2 (es) Anticuerpos contra ilt2 y uso de los mismos
MX2020006171A (es) Terapia de combinacion con anticuerpos anti interleucina-8 (il-8) y anticuerpos anti receptor de muerte programada (pd-1) para tratar cancer.
CO6382138A2 (es) N-cadherina: blanco para diagnosis y terapia de cáncer
BR112015031950A2 (pt) métodos para tratamento de câncer de ovário
MX2022003190A (es) Terapias de combinacion para el tratamiento de cancer que comprenden un derivado de bacterioclorofila.
BRPI0806257A2 (pt) método de tratamento, e, uso de uma composição imunoterapêutica
WO2020180712A8 (en) Anti-tnfr2 antibodies and uses thereof
BR112016023011A2 (pt) tratamento de câncer gástrico

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE A 4A ANUIDADE.